Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

NCT05523440 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Funding issue.

Conditions

Recurrent Endometrial Carcinoma
Recurrent Ovarian Carcinoma
ARID1A Gene Mutation

Interventions

DRUG: Bevacizumab
DRUG: Niraparib

Sponsor

University of Oklahoma

Collaborators

[object Object]
[object Object]